0.4891USD-2.20%Mkt Cap: 10.47M USDP/E: —Last update: 2026-06-01
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the tr…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap10.47M USD
Enterprise Value7.61M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-5.45M USD
Revenue/Share—
Last Price0.4891 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.76
PEG—
EV/EBITDA-1.30
EV/Revenue—
P/S—
P/B1.67
EPS (TTM)-0.30
EPS (Forward)-0.67
52W Range
0.40005% of range2.110
52W High2.110 USD
52W Low0.4000 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-85.90%
ROA-83.29%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.44M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-17.32%
Net Debt-3.67M USD
Net Debt/EBITDA0.63
Balance Sheet
Debt/Equity—
Current Ratio10.31
Quick Ratio8.53
Book Value/Sh0.3050 USD
Cash/Share0.1720 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)8.000 USD
Target Range4.000 USD – 12.00 USD
# Analysts2
Ownership
Shares Out.21.41M
Float12.42M
Insiders37.20%
Institutions6.94%
Short Interest
Short Ratio0.8d
Short % Float0.83%
Short % Out.0.57%
Shares Short121.33K
Short (prev mo.)146.65K
Technical
SMA 500.5711 (-14.4%)
SMA 2000.8537 (-42.7%)
Beta—
S&P 52W Chg27.94%
Avg Vol (30d)165.36K
Avg Vol (10d)190.12K
Technical Indicators
RSI (14)43.0
MACD-0.0186
MACD Signal-0.0216
MACD Hist.+0.0030
BB Upper0.5890 USD
BB Middle0.5208 USD
BB Lower0.4526 USD
BB Width26.21%
ATR (14)0.0431 USD
Vol Ratio (20d)0.66x